Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBT (2021 - 2025)

Historic EBT for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to -$13.7 million.

  • Kezar Life Sciences' EBT rose 3639.95% to -$13.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$70.8 million, marking a year-over-year increase of 2818.05%. This contributed to the annual value of -$83.7 million for FY2024, which is 1780.11% up from last year.
  • As of Q2 2025, Kezar Life Sciences' EBT stood at -$13.7 million, which was up 3639.95% from -$16.6 million recorded in Q1 2025.
  • In the past 5 years, Kezar Life Sciences' EBT ranged from a high of -$13.0 million in Q2 2021 and a low of -$32.3 million during Q4 2023
  • Moreover, its 5-year median value for EBT was -$18.2 million (2022), whereas its average is -$19.2 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 7743.8% in 2023, then surged by 3732.8% in 2024.
  • Kezar Life Sciences' EBT (Quarter) stood at -$14.2 million in 2021, then fell by 27.93% to -$18.2 million in 2022, then plummeted by 77.44% to -$32.3 million in 2023, then soared by 37.33% to -$20.2 million in 2024, then skyrocketed by 32.22% to -$13.7 million in 2025.
  • Its EBT was -$13.7 million in Q2 2025, compared to -$16.6 million in Q1 2025 and -$20.2 million in Q4 2024.